BioNTech SE (BNTX)
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Address
AN DER GOLDGRUBE 12
MAINZ, 2M 55131
Founded
2008
Number of Employees
3,082
Website
http://www.biontech.de
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at BNTX make a trade.
Creating a free account takes less than one minute